BCL9L and cholangiocarcinoma: In our study, we found that LINC00665 was upregulated and predicted poor prognosis in CCA patients, and silencing LINC00665 impaired gemcitabine tolerance, repressed EMT and stemness, and inactived Wnt/β-Catenin signaling through miR-424-5p/BCL9L axis.